作者: Caroline Jochems , Jeffrey Schlom , James L. Gulley
DOI: 10.1007/978-3-7091-1818-4_10
关键词: Clinical trial 、 Immune system 、 Cancer research 、 Tumor cells 、 Chemotherapy 、 Cancer 、 Antigen 、 Costimulatory Molecule 、 Immune checkpoint inhibitors 、 Medicine
摘要: TRICOM poxviral-based vaccines are novel “off-the-shelf” agents designed to generate a robust immune response against tumor-associated antigens, which commonly expressed on tumor cells. In this chapter, we elucidate the science behind development and use of these vaccines. We also highlight results preclinical clinical trials potential benefits combining them with standard-of-care chemotherapy other immunotherapies.